News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medisyn Technologies, Inc. Awarded Phase I SBIR Grant by Department of Defense to Discover and Develop Novel NSAIDs with Reduced GI Toxicity


1/25/2008 9:07:45 AM

MINNEAPOLIS--(BUSINESS WIRE)--Medisyn Technologies today announced that the company was recently awarded a Small Business Innovation Research (SBIR) Phase I grant from the Department of Defense (DoD) to discover and develop new non-steroidal anti-inflammatory drugs (NSAIDs) with reduced gastrointestinal toxicity. NSAIDs devoid of GI toxicity that may be potentially available without a prescription (over-the-counter) enables easier access for deployed military personnel.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES